Last reviewed · How we verify
Hib conjugate vaccine
The Hib conjugate vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b by conjugating the bacterial polysaccharide capsule to a protein carrier.
The Hib conjugate vaccine stimulates the immune system to produce antibodies against Haemophilus influenzae type b by conjugating the bacterial polysaccharide capsule to a protein carrier. Used for Prevention of invasive Haemophilus influenzae type b disease (meningitis, epiglottitis, bacteremia, pneumonia), Routine childhood immunization.
At a glance
| Generic name | Hib conjugate vaccine |
|---|---|
| Sponsor | Public Health England |
| Drug class | Conjugate vaccine |
| Target | Haemophilus influenzae type b polysaccharide capsule |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains the polysaccharide capsule of Haemophilus influenzae type b conjugated to a protein carrier (such as diphtheria toxoid or meningococcal protein), which enhances immunogenicity and T-cell dependent responses. This conjugation allows the vaccine to elicit both antibody production and immunological memory, providing protection against invasive Hib disease including meningitis, epiglottitis, and bacteremia.
Approved indications
- Prevention of invasive Haemophilus influenzae type b disease (meningitis, epiglottitis, bacteremia, pneumonia)
- Routine childhood immunization
Common side effects
- Local injection site reactions (erythema, swelling, pain)
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Exploratory Clinical Study of MT-2301 (PHASE2)
- BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies (PHASE3)
- A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants (PHASE2)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- Phase IV Clinical Study of sIPV Administration in Adolescent and Adult Populations (PHASE4)
- Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants (PHASE1, PHASE2)
- Phase 3 Study of BK1310 in Healthy Infants (PHASE3)
- Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hib conjugate vaccine CI brief — competitive landscape report
- Hib conjugate vaccine updates RSS · CI watch RSS
- Public Health England portfolio CI